

Introduction

dabl® is a unique partnership of experts in clinical management and research, management techniques and technology. With a strong clinical background, dabl® is not simply an IT company in the medical field. dabl® develops online cardiovascular systems and research solutions for the prevention and management of high blood pressure, stroke, heart attack, heart disease and a range of other cardiovascular conditions. The company was founded in 2000 by William Rickard and Prof Eoin O'Brien. It has grown internationally since its foundation and currently operates in 9 countries.

SOME FACTS ABOUT CARDIOVASCULAR DISEASE (CVD) - GLOBAL

- CVD is the number one cause of death globally: more people die annually from CVD than from any other cause.
- An estimated 17.1 million people died from CVD in 2004, representing 29% of all global deaths. Of these deaths, an estimated 7.2 million were due to coronary heart disease and 5.7 million due to stroke.
- Low- and middle-income countries are disproportionately affected: 82% of CVD deaths take place in low- and middle-income countries and occur almost equally in men and women.
- By 2030, almost 23.6 million people will die from CVD, mainly from heart disease and stroke.

Source: WHO (www.who.int)

SOME FACTS ABOUT CARDIOVASCULAR DISEASE (CVD) - IRELAND

- High blood pressure: In 2007 nearly 852,000 adults (25.1%) had high blood pressure. By 2020 this is expected to rise to over 1,192,000 people - an additional 341,000 adults (a 40% increase in less than 15 years).
- Coronary Heart Disease (CHD): In 2007 nearly 131,000 adults (3.8%) had Coronary Heart Disease (CHD, angina and heart attack). By 2020 this is expected to rise to over 195,000 people - an additional 65,000 people (a 50% increase in less than 15 years).
- Stroke: In 2007 almost 59,000 adults (1.7%) have had a stroke. By 2020 this is expected to rise to almost 87,000 people – an additional 28,000 adults (an increase of 48% in less than 15 years).
- Diabetes (Type 1 and Type 2 combined): In 2007 nearly 144,000 adults (4.5%) have diabetes (Type 1 and Type 2 combined). By 2020 this is expected to rise to over 233,000 an additional 89,000 adults – (a 62% increase in less than 15 years).

Source: IPH Study "Making Chronic Conditions Count" (Mar 2010)

High blood pressure (hypertension) is a major cause of heart disease and stroke.

WHAT THE EXPERTS SAY:

- *"We need to be innovative and turn our attention to reversing the present ambivalent attitude to the management of hypertension so as to obtain control of blood pressure. If we do so, we can prevent up to 5,000 strokes per annum in Ireland".*



- *“Since conventional blood pressure (BP) measurement was introduced over a century ago, in 1881, we have landed men on the moon, encircled Mars, invented the automobile and airplane, and, most importantly, revolutionized the technology of science with the microchip. Why, we might ask, has medicine ignored scientific evidence for so long so as to perpetuate a grossly inaccurate measurement technique in both clinical practice and hypertension research?”*
- *“The diagnosis of hypertension is being misdiagnosed in as many as one third of all patients attending for routine BP measurement.”*

Prof Eoin O’Brien, Professor of Molecular Pharmacology, Conway Institute of Biomolecular and Biomedical Research, UCD.

ABOUT dabl®

Based in Dublin, Ireland, dabl® develops cardiovascular healthcare systems for the **prevention** and **management** of high blood pressure, stroke, heart-attack and a range of other cardiovascular diseases.

The dabl® systems are designed, developed and updated in close collaboration with major centres of excellence worldwide headed by our international [dabl® Medical Advisory Board](#).

Our systems are used internationally by GPs, Hospitals, Pharmacies, Health Screening Centres, Pharmaceutical companies, Research Centres and National Health Authorities.

The dabl® systems provide a high level of accuracy in diagnosis using real-time data, enabling the medical team to concentrate on quality decision making, managing the patient and achieving better outcomes. To date, over €7 million has been invested in R&D.

dabl® has evolved out of specialist care and research and over the years has moved out to primary/community care. In 2008 the company launched diagnostic and management services to the pharmacy sector. In December 2009, the implementation of the [dabl® National Cardiovascular Shared Care System](#), linking primary and secondary care, commenced in Ireland.

PRODUCT RANGE

Our range of productivity tools helps medical professionals to make more informed treatment decisions. They include:

[dabl® ABPM range](#) - All the research now shows that the only way to accurately diagnose and manage hypertension is to use 24-hr ABPM. The dabl® ABPM system is the only expert online system for the most accurate diagnosis and management of hypertension using 24-hour ABPM (Ambulatory Blood Pressure Measurement). The system links to a number of validated ABPM devices and produces a one-page interpreted report. Different versions are available for GPs, Pharmacies, Health Screening Centres, Hospitals and Specialist (Research) Centres.



[dabl® Anticoagulant](#) - Online system for the management of patients on anticoagulant (warfarin) treatment. INR results can be uploaded automatically from an INR device or entered manually to calculate the dose and next appointment for the patient. A user-friendly plot to monitor INR over the course of treatment is produced by the system to give a quick visualisation of patient status. Available for use in GP Practices, Hospitals & Pharmacies.

[dabl® Cardiovascular](#) - Comprehensive online cardiovascular system for hospitals that provides evidenced based diagnosis and management of patients with cardiovascular issues, reducing the number of incidences of stroke and heart attack in the community.

[dabl® Geriatric](#) - An additional module available with the **dabl® Cardiovascular** system, used for the assessment and management of elderly patients. The module is designed to assist the physician with a comprehensive evaluation and an ongoing management tool for the elderly. For the patient it is used to ascertain the values of six major quality of life indices and provide an automatic summary for the medical team.

[dabl® Research](#) - ABPM and HBPM are now increasingly used both to test anti-hypertensive drug efficacy in clinical trials and also as a cardiac safety biomarker. dabl® provides proven centrally hosted systems for ease of implementation and standardised data validation and analysis for multi-centre clinical trials.

Media Contact:

If you have a media query please contact Paula O’Sullivan on +353 1 2780247 or email paula.osullivan@dabl.ie

Guidelines for use of dabl® name - IMPORTANT

The dabl® name is our registered trade mark and brand logo. It is therefore essential that everywhere the dabl® name is used, it is written or displayed in exactly this format “dabl® “

If you cannot include the registered trade mark superscripted, always ensure, as a minimum, the name or all letters are in lower case e.g. dabl

The use of our registered trade mark and logo in its correct format is an important part of our brand. We therefore ask that you are consistent in the correct use of our brand name.